Approval Date: Dec 2022
In combination with other antiretrovirals, this drugs is indicated for treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection
Approval Date: Dec 2022
Indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis
Approval Date: Nov 2022
A first-in-class medication, this drug is indicated to delay the onset of Stage 3 type 1 diabetes, potentially delaying the clinical diagnosis of type 1 diabetes to provide patients with months to years without the burdens of disease.
Approval Date: Sep 2022
Indicated to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations
Approval Date: Sep 2022
Indicated for the topical treatment of plaque psoriasis of up to 20% body surface area involvement
Approval Date: Sep 2022
Indicated for the treatment of hypertension, to lower blood pressure
Approval Date: Sep 2022
Indicated for the treatment of HIV-1 infection
Approval Date: Sep 2022
Indicated for the treatment of moderate-to-severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy
Approval Date: Aug 2022
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Approval Date: Aug 2022
Indicated for the adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)
